Physician profile
Robert G Stern
NPI 1134272495
$14,655.30
in general payments reported to CMS, 2019-2025
20 companies · $466 in 2025
The $466 reported for 2025 was more than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $97.39 · 2022: $41.03 · 2023: $9,683 · 2024: $4,367 · 2025: $466.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $7,755 · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $2,450 · Food and Beverage: $1,470 · Consulting Fee: $1,470 · Travel and Lodging: $1,372.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $7,755.00 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $2,450.00 |
| Food and Beverage | $1,470.14 |
| Consulting Fee | $1,470.00 |
| Travel and Lodging | $1,371.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $13,435.86 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $365.04 | 2023-2025 | Spravato, Invega Sustenna |
| Lilly USA, LLC | $138.47 | 2024-2025 | Amyvid, Kisunla |
| Neurocrine Biosciences, INC. | $95.63 | 2023-2025 | Ingrezza |
| Teva Pharmaceuticals USA, INC. | $95.42 | 2023-2025 | Austedo Xr, Austedo Xr |
| Biogen, INC. | $85.39 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $66.48 | 2024-2025 | Caplyta |
| Takeda Pharmaceuticals U.S.A., INC. | $65.70 | 2023-2025 | Trintellix |
| Lundbeck LLC | $52.34 | 2022-2025 | Rexulti |
| Abbvie INC. | $40.98 | 2023-2024 | Vraylar |
| Otsuka America Pharmaceutical, INC. | $36.16 | 2023-2024 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| E.R. Squibb & Sons, L.L.C. | $34.84 | 2025 | Cobenfy |
| Alkermes, INC. | $33.81 | 2023 | Aristada, Lybalvi |
| Life Molecular Imaging LTD | $30.58 | 2024-2025 | Neuraceq |
| Vanda Pharmaceuticals INC. | $27.60 | 2022-2025 | Fanapt |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acadia Pharmaceuticals INC | $18.99 | 2024 | Nuplazid |
| Corium, LLC | $17.49 | 2024 | Azstarys |
| Indivior INC. | $14.52 | 2023 | Perseris |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Stern listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.